A press release from Novo Nordisk, comparing Novo's Tresiba to French Sanofi's insulins, was misleading, against the Medicines Act and a violation of good marketing practice. This is the judgment of the Danish Maritime and Commercial High Court.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.